Hormone Replacement Therapy Supply Guide: Patches, Injectables, and What Facilities Need to Know About HRT Procurement

Why This Is a Procurement Problem, Not Just a Supply Problem

If you manage a medical practice, women’s health clinic, or med spa that prescribes or dispenses menopausal hormone therapy, you already know the script. A patient arrives for her estradiol patch refill. It is not available from your primary supplier. The backup is on allocation. The pharmacist down the street is out, too.

Now you are explaining to a patient — whose hot flashes just returned — that she needs to switch formulations, adjust her dosing schedule, and wait to see how her body responds to something new. This scenario is playing out across thousands of facilities nationwide.

The facilities navigating this shortage successfully are not the ones with better luck. They are the ones that built procurement strategies before the backorder notice arrived. This guide provides the framework to do exactly that: diversify your hormone replacement therapy supplies, establish multi-supplier relationships, and keep patients on effective menopausal hormone therapy without interruption.

How We Got Here: The Estradiol Patch Shortage Explained

The estradiol patch shortage did not happen overnight. It is the result of three converging forces that have strained a supply chain with little margin for disruption.

Bayer Climara Discontinuation

In late 2023, Bayer discontinued its Climara estradiol patch, removing one of the most widely prescribed transdermal brands from the U.S. market. That left a handful of manufacturers producing the majority of estradiol transdermal patches: Sandoz, Viatris (formerly Mylan), Amneal, Noven, and Zydus.

When five companies supply a product category where demand is growing by double digits annually, any single disruption tips the balance. The Climara exit did exactly that.

FDA Black Box Warning Removal

In November 2025, the FDA removed the black box warning from menopausal hormone therapy products. The warning had been in place since the early 2000s following the Women’s Health Initiative (WHI) study, which overstated cardiovascular and cancer risks for younger menopausal women.

The North American Menopause Society (NAMS) and other clinical organizations had long argued the warning was outdated and discouraged appropriate treatment. Its removal was evidence-based and overdue. But it also triggered a wave of new prescriptions at exactly the moment manufacturing capacity was already strained.

Demand Growth Outpacing Supply

The 86% increase in HRT prescriptions since 2021 reflects a broader cultural and clinical shift. Menopause awareness campaigns, updated NAMS guidelines, and the FDA’s regulatory changes have combined to normalize hormone therapy after two decades of underuse.

CNN reported in February 2026 that Sandoz acknowledged it takes the shortage “very seriously” and is shipping additional product to the U.S. However, supply constraints are expected to continue through mid-2026, with some products on backorder into the second half of the year.

The HRT Product Landscape: What Is Available and What Is Constrained

Understanding the full landscape of menopausal hormone therapy supplies is essential for building a resilient formulary. Below is a breakdown by delivery form.

Transdermal Patches

• Vivelle-Dot (estradiol): Limited / Allocation
• Climara Pro (estradiol/levonorgestrel): Discontinued by Bayer
• Dotti (estradiol): Intermittent availability
• Alora (estradiol): Limited
• Minivelle (estradiol): Variable by region

Transdermal patches remain the gold standard per NAMS guidelines because they provide steady estrogen delivery with lower venous thromboembolism (VTE) risk compared to oral formulations. However, patches are currently the most supply-constrained category.

Topical Gels and Emulsions

• EstroGel (estradiol gel): Generally available
• Divigel (estradiol gel): Generally available
• Elestrin (estradiol gel): Generally available
• Estrasorb (estradiol emulsion): Limited

Estradiol gel products are the strongest alternative to patches. They share the transdermal absorption pathway, offering similar VTE risk advantages over oral tablets. Supply has remained more stable because gel manufacturing does not face the same adhesive and matrix production bottlenecks as patches.

Topical Sprays

• Evamist (estradiol spray): Generally available

Evamist provides another transdermal option with generally stable supply. It is less commonly prescribed but worth adding to formulary as a backup delivery form.

Oral Tablets

• Premarin (conjugated estrogens): Generally available
• Estrace (estradiol): Generally available
• Bijuva (estradiol/progesterone): Generally available

Oral tablets are the most widely available delivery form. However, they carry a higher VTE risk compared to transdermal options and undergo first-pass hepatic metabolism. For patients with VTE risk factors, obesity, or liver concerns, oral may not be the appropriate switch from patches.

Injectable Estrogen

• Delestrogen (estradiol valerate): Variable / Allocation
• Depo-Estradiol (estradiol cypionate): Variable

Estradiol injections provide a viable option for patients who prefer less frequent dosing or cannot use transdermal products. Injectable estrogen availability has been intermittent, so facilities should maintain secondary sources.

Vaginal and Local Estrogen

• Vagifem/Yuvafem (estradiol vaginal tablets): Generally available
• Estrace Cream (estradiol vaginal cream): Generally available
• Imvexxy (estradiol vaginal inserts): Generally available
• Femring (estradiol vaginal ring): Generally available

Vaginal products serve a different clinical purpose — primarily treating genitourinary syndrome of menopause (GSM) rather than systemic menopausal symptoms. These products have maintained stable supply and are not interchangeable with systemic HRT for most patients.

Progesterone and Combination Therapy Supply Status

Facilities prescribing estrogen to patients with an intact uterus must also maintain progesterone supply for endometrial protection. Prometrium (micronized progesterone) has remained generally available, though facilities should monitor for any allocation changes as estrogen prescribing increases.

Medroxyprogesterone acetate (Provera) is also widely available. Combination products like Bijuva (estradiol/progesterone capsule) and Activella (estradiol/norethindrone acetate) simplify regimens but limit formulary flexibility during shortages. Stocking individual components provides more switching options.

503B Compounding Pharmacies: A Regulated Alternative

When FDA-approved products are unavailable, compounding pharmacies enter the conversation. Facilities need to understand the regulatory landscape before pursuing this route.

503A vs. 503B: The Critical Distinction

503A pharmacies compound individual prescriptions for specific patients based on a prescriber’s order. They are regulated primarily by state boards of pharmacy and do not require FDA registration for standard compounding.

503B outsourcing facilities operate under direct FDA oversight and can produce compounded medications in larger quantities without patient-specific prescriptions. They must comply with current good manufacturing practices (cGMP), report adverse events to the FDA, and submit to regular FDA inspections.

For facilities seeking to stock bioidentical hormone therapy products, 503B outsourcing facilities offer a more regulated and scalable option than traditional 503A compounding pharmacies.

Pros and Cons for Facilities

• Custom dosing and formulations when commercial products are unavailable
• 503B facilities can supply office stock without patient-specific prescriptions
• May offer delivery forms (troches, pellets, custom-strength creams) not commercially available
• Can fill gaps during acute shortages of FDA-approved products

• Compounded products are not FDA-approved and do not undergo the same efficacy and safety review as commercial drugs
• Quality varies between facilities; FDA has issued warning letters to non-compliant compounders
• Insurance coverage is often limited or unavailable for compounded hormones
• DSCSA traceability requirements differ for compounded products

NAMS Position on Compounded Bioidentical Hormones

NAMS has stated that FDA-approved hormone therapy products should be used preferentially over compounded preparations when available. Compounded bioidentical hormones are not inherently safer or more effective than FDA-approved bioidentical options like Estrace or Prometrium. However, NAMS acknowledges that compounding may be appropriate when a patient requires a dosage or delivery form not commercially available.

Facilities should document clinical rationale when prescribing compounded hormones and prioritize 503B outsourcing facilities with clean FDA inspection histories.

Cost Comparison Across Delivery Forms

Pricing fluctuates based on contracts, generics availability, and shortage premiums. The following ranges represent typical wholesale acquisition cost (WAC) estimates for a 30-day supply.

• Transdermal Patch: Vivelle-Dot (generic)
• Topical Gel: Divigel / EstroGel (generic)
• Oral Tablet: Estrace (generic estradiol)
• Injectable: Delestrogen (generic)
• Vaginal: Yuvafem (generic)
• 503B Compounded: Custom formulation

Gels represent the best cost-to-clinical-profile balance when patches are unavailable.

GPO Contracts and Bulk Purchasing Strategies

• Commit volume across delivery forms. GPO contracts that bundle patches, gels, and injectables from the same manufacturer often secure better allocation priority during shortages.
• Lock in allocation agreements. Some GPO contracts guarantee minimum allocation percentages based on historical purchasing.
• Review contract terms quarterly. Shortage-driven price increases can erode GPO savings. Ensure your contract includes price protection clauses.
• Consider regional purchasing cooperatives. Smaller practices that do not qualify for national GPO membership can join regional cooperatives to achieve similar benefits.

How to Build a Reliable HRT Procurement Strategy

Waiting for your distributor to resolve a backorder is not a procurement strategy. These five steps build resilience into your hormone therapy supply chain.

Step 1: Diversify Across Delivery Forms, Not Just Brands

Most facilities experiencing critical shortages had concentrated their entire HRT formulary in transdermal patches. When patches went on allocation, they had no clinical alternative ready.

Build formulary depth across at least three delivery forms: patches, gels, and one additional option (oral, injectable, or spray). Pre-approve substitution protocols with your clinical team so switches can happen the same day a shortage is confirmed.

Step 2: Establish Relationships With Multiple Distributors

Allocation during shortages is typically based on purchase history. If your facility has never ordered from a particular distributor, you will receive zero allocation when supply is constrained.

Establish active accounts with at least two distributors and place regular orders — even small ones — to build purchase history. USA MedPremium, for example, carries menopause treatment supplies across multiple delivery forms and manufacturers, ships DSCSA-compliant from Florida nationwide, and can serve as a secondary or tertiary source alongside your primary distributor.

Step 3: Monitor Shortage Databases Proactively

Do not wait for a backorder notification. Monitor these sources weekly:

• ASHP Drug Shortage Database — the most comprehensive source for current shortage status and estimated resolution dates
• FDA Drug Shortage Database — includes manufacturer communications and regulatory updates
• Manufacturer direct communications — sign up for allocation alerts from Sandoz, Viatris, Amneal, and other HRT manufacturers

Step 4: Build Safety Stock for High-Volume Products

For your top five HRT products by prescription volume, maintain a 30-day safety stock beyond your normal reorder cycle. This buffer absorbs short-term allocation disruptions without forcing immediate patient switches.

Calculate safety stock using your average monthly dispensing volume plus a 20% shortage buffer. Review quarterly and adjust based on ASHP shortage severity ratings.

Step 5: Document Everything for Compliance and Continuity

Maintain records of shortage communications, substitution decisions, and patient notifications. This documentation supports clinical continuity if patients transfer between providers and demonstrates due diligence for regulatory compliance.

DSCSA Compliance in HRT Sourcing

The Drug Supply Chain Security Act (DSCSA) requires electronic, serialized traceability for every prescription product moving through the U.S. supply chain. During HRT shortages, compliance risk increases as facilities source from unfamiliar suppliers.

What Facilities Must Verify

Before purchasing hormone therapy products from any new supplier:

• Confirm the supplier holds valid state and federal licenses. Request copies and verify with the relevant state board of pharmacy.
• Verify serialized transaction data. Every unit must include a transaction information document (TI), transaction history (TH), and transaction statement (TS).
• Check for FDA warning letters. Search the FDA’s inspection database for any compliance actions against the supplier.
• Validate product serialization. Scan product barcodes against the manufacturer’s verification system to confirm authenticity.

Compounded Products and DSCSA

503B outsourcing facility products have specific DSCSA requirements that differ from commercially manufactured drugs. Facilities must confirm that their 503B supplier provides adequate lot-level traceability even where full serialization may not be required.

Talking to Patients About HRT Switches

Forced formulation changes create anxiety. Patients who finally found an HRT regimen that works are understandably resistant to switching. A structured communication approach reduces friction and improves adherence.

Pre-Build Substitution Protocols

Develop written protocols for the three most likely switches from your current high-volume HRT products. Each protocol should include:

• The clinical rationale for the alternative
• Dosing equivalence (see reference table below)
• Expected timeline for therapeutic effect
• Specific side effects to monitor during the transition
• Follow-up schedule (typically 4-6 weeks post-switch for symptom and level assessment)

Dosing Equivalence Communication

Patients need to understand that switching delivery forms does not mean starting over. Explain that the active ingredient — estradiol — is the same across patches, gels, and other formulations. What changes is the delivery method and potentially the dosing frequency.

Patient Handout Best Practices

Prepare a one-page handout covering:

• Why the switch is necessary (supply shortage, not a clinical concern with their current product)
• What the new product is and how to use it
• What to expect during the first 2-4 weeks
• When to contact the office (breakthrough symptoms, skin reactions, unusual side effects)
• Reassurance that a return to their preferred product is possible when supply normalizes

Dosing Equivalence Quick Reference

The following table provides approximate equivalences for common estradiol formulation switches. Individual patient response varies. Clinical monitoring and dose adjustment are always required after switching.

• Estradiol patch 0.05 mg/day: Estradiol gel 0.75 mg/day (EstroGel 1 pump)
• Estradiol patch 0.05 mg/day: Oral estradiol 1 mg/day
• Estradiol patch 0.1 mg/day: Estradiol gel 1.5 mg/day (EstroGel 2 pumps)
• Estradiol patch 0.05 mg/day: Estradiol valerate injection 10-20 mg IM q2-4 weeks
• Estradiol patch 0.0375 mg/day: Divigel 0.5 mg/packet daily

This table is for clinical reference only. All dosing changes should be individualized based on patient response, serum estradiol levels, and clinical judgment.

Next Steps for Your Facility

The hormone therapy shortage is not resolving quickly. Facilities that build diversified procurement strategies now will maintain patient continuity while competitors scramble for allocation.

USA MedPremium can help. We carry hormone replacement therapy supplies across multiple delivery forms and manufacturers — estradiol patches, gels, injectables, oral tablets, and vaginal estrogen products. Every product ships DSCSA-compliant from our Florida distribution centers with full serialized traceability.

View our extended Pharmacy and prescription category for a full look at what’s available.

Contact a USA MedPremium representative for a shortage consultation and customized procurement checklist for your facility’s HRT formulary.